In:
Aging Health, Future Medicine Ltd, Vol. 9, No. 6 ( 2013-12), p. 619-627
Abstract:
Lifelong vaccination can be seen as one of the cornerstones of healthy aging. Nowadays, the cost–effectiveness question is generally raised, particularly with regard to vaccines. Healthy aging also needs to be cost effective. Cost–effectiveness analysis is conducted with well-defined guidelines that are, for example, available for both The Netherlands and Belgium. This article considers cost–effectiveness of lifelong vaccination and the application of such guidelines, exemplified with vaccination against rotavirus, pertussis and pneumococcal infections to protect infants, adolescents, adults and elderly individuals against these infections. Notably, guidelines for both countries show similarities (differential discounting) and differences (inclusion of indirect costs and quality-adjusted life year gains for parents/caregivers) that impact upon vaccine analyses.
Type of Medium:
Online Resource
ISSN:
1745-509X
,
1745-5103
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2013
Bookmarklink